John A. Stalfort III

Filings by John A. Stalfort III span 3 companies, the busiest being Acumen Pharmaceuticals, Inc., Taysha Gene Therapies, Inc. and Verrica Pharmaceuticals Inc. The record holds 13 filings, for trades running from 6 July 2021 to 3 June 2026.

No open-market sale appears; the market trades are 5 purchases worth €1.6M. The totals exclude 1 filing filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 4 share grants.

Half of the purchases are above €398k and half below. Clusters matter here: 3 out of 4 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The latest filing, published on 5 June 2026, reports a share grant in Acumen Pharmaceuticals, Inc. The clock since the last published purchase (26 November 2024) now reads 697 days. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.